Skip to main content
. 2013 Apr 23;7(4):840–849. doi: 10.1016/j.molonc.2013.04.004

Figure 2.

Figure 2

Ectopic RUNX3 protein expression in pancreatic cancer cell lines. Eukaryotic expression constructs for CAT (mock) and RUNX3 were introduced into PANC‐1, MIAPaCa‐2, and BxPC‐3 cells. (A) Immunoblot analysis of RUNX3 and MRP expression. Immunoblot analysis was performed using antibodies against RUNX3, MRP1, MRP2, MRP5, and α‐actin. Immunoblotting for α‐actin was done to verify equal loading. These 3 cell lines were originally endogenous RUNX3 negative. The left lane for each cell line represents mock‐transfected cancer cells, and the right lane represents RUNX3‐transfected cancer cells. Representative blots of more than 3 independent experiments. (B) Cell growth activity. Cell proliferative activities were measured by MTT assay. All results are expressed as ratios compared to day 1. Data represent the means ± SE of more than 3 independent experiments performed in triplicate. *P < 0.05; **P < 0.01, versus mock‐transfected cells (Student's t test). (C–E) Gemcitabine sensitivity. PANC‐1 (C), MIAPaCa‐2 (D), and BxPC‐3 (E) cell lines were treated with various concentrations of gemcitabine for 24 h. Cell viability was measured by MTT assay and expressed as a percentage relative to control cells. Data represent the means ± SE of more than 3 independent experiments performed in triplicate.